We have an exciting portfolio of clinical-stage, nanotechnology-based therapies for common dermatology conditions. These conditions are typically characterised by underlying infection and inflammation, and where current treatment options don’t meet the patient needs.

Blueberry operates with a highly experienced drug discovery and clinical development team who have taken medicines from initial idea to the market. Our team collaborates with a range of academic and industrial partners and outsource providers to deliver our programmes.